We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · January 11, 2023

Molnupiravir Plus Usual Care vs Usual Care Alone as Early Treatment for Adults With COVID-19 at Increased Risk of Adverse Outcomes

The Lancet


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial
Lancet 2022 Dec 22;[EPub Ahead of Print], CC Butler, FDR Hobbs, OA Gbinigie, NM Rahman, G Hayward, DB Richards, J Dorward, DM Lowe, JF Standing, J Breuer, S Khoo, S Petrou, K Hood, JS Nguyen-Van-Tam, MG Patel, BR Saville, J Marion, E Ogburn, J Allen, H Rutter, N Francis, NPB Thomas, P Evans, M Dobson, TA Madden, J Holmes, V Harris, ME Png, M Lown, O van Hecke, MA Detry, CT Saunders, M Fitzgerald, NS Berry, L Mwandigha, U Galal, S Mort, BD Jani, ND Hart, H Ahmed, D Butler, M McKenna, J Chalk, L Lavallee, E Hadley, L Cureton, M Benysek, M Andersson, M Coates, S Barrett, C Bateman, JC Davies, I Raymundo-Wood, A Ustianowski, A Carson-Stevens, LM Yu, P Little

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading